| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | BLR1; CD185; MDR15 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CXCR5 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于C8B抗体的示例参考文献(内容为虚构模拟，仅供格式参考)：
1. **文献名称**：Structural characterization of the C8β antibody binding site in complement component C8
**作者**：Smith J, et al.
**摘要**：本研究通过X射线晶体学解析了C8B蛋白与特异性抗体的复合物结构，揭示了抗体识别C8β亚基的抗原表位，为开发靶向补体系统的治疗性抗体提供了结构基础。
2. **文献名称**：C8β autoantibodies in atypical hemolytic uremic syndrome: diagnostic implications
**作者**：Zhang L, et al.
**摘要**：发现非典型溶血尿毒综合征(aHUS)患者血清中存在C8B自身抗体，实验证明这些抗体通过干扰补体膜攻击复合物(MAC)的组装导致血管内皮损伤，提示其作为疾病生物标志物的潜力。
3. **文献名称**：Development of a high-affinity anti-C8β monoclonal antibody for complement pathway inhibition
**作者**：Garcia R, et al.
**摘要**：报道了一种新型抗C8B单克隆抗体的开发，该抗体能特异性阻断补体终末通路中C8与C9的结合，在动物模型中显著减轻炎症性组织损伤，展现治疗补体过度激活相关疾病的转化价值。
注：以上内容为根据领域常见研究方向模拟生成，实际文献需通过PubMed/Google Scholar等平台检索获取。
The C8B antibody targets the beta subunit of complement component 8 (C8β), a critical protein in the complement system’s membrane attack complex (MAC). C8. composed of α, β, and γ subunits, plays a pivotal role in immune defense by inserting into pathogen membranes, facilitating MAC pore formation, and inducing cell lysis. The C8B gene encodes the β-subunit, which stabilizes C8 and enables its interaction with other MAC components (C5b-7. C9) during terminal complement activation.
C8B antibodies are primarily used in research and diagnostics to study complement-mediated pathologies. Dysregulation of the MAC is implicated in autoimmune disorders (e.g., paroxysmal nocturnal hemoglobinuria), inflammatory conditions, and tissue injury. These antibodies help detect C8β expression in biological samples, aiding in disease mechanism studies or biomarker identification. Additionally, they are explored in therapeutic contexts, such as monitoring complement inhibition therapies (e.g., anti-C5 drugs) or developing targeted treatments for complement-driven diseases.
Commercial C8B antibodies are typically monoclonal or polyclonal, validated for applications like Western blotting, immunohistochemistry, or flow cytometry. Research on C8B also contributes to understanding genetic deficiencies linked to increased susceptibility to bacterial infections, particularly Neisseria species. Overall, C8B antibodies serve as essential tools for dissecting complement biology and its clinical implications.
×
